Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J., Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc.

Inc. (NYSE American: PTN) has announced the completion of their Phase 2 clinical trial for an obesity treatment, marking a ...

Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

While it may seem strange that politics could impact the price of popular weight loss drugs, it is a definite possibility.

Squirro, a leading enterprise GenAI platform provider, has today announced it closed out the second half of 2024 with a year-on-year increase in revenue of almost 60% and growth forecast to exceed ...

SainSmart announced the launch of the Genmitsu PROVerXL 4X4 CNC Machine, a next-generation CNC router designed to bring industrial precision and efficiency to small businesses and makers. It is an ...